Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS · Delayed Price · Currency is USD
0.101
-0.010 (-9.01%)
Mar 5, 2026, 4:00 PM EST
55.38%
Market Cap 18.24M
Revenue (ttm) n/a
Net Income (ttm) -3.43M
Shares Out 172.57M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,899
Average Volume 39,760
Open 0.110
Previous Close 0.111
Day's Range 0.101 - 0.120
52-Week Range 0.034 - 0.123
Beta -0.36
RSI 59.16
Earnings Date Mar 27, 2026

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol INTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.